Alternatives to Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a Biotechnology tool: biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
Viridian Therapeutics, Inc. profileMore Biotechnology alternatives
The 20 closest Biotechnology companies to Viridian Therapeutics, Inc.
- Website
argenx49BiTechAmsterdam, Netherlands$51.1MGlobal immunology company developing antibody-based therapies for severe autoimmune diseases.
- Website
Dren Bio48BiotechSan Carlos, United States$156.0MBiopharmaceutical company developing antibody therapeutics for cancer and autoimmune diseases.
- Website SASana Biotechnology47BiotechSeattle, United States
Biotechnology company developing cell and gene therapies for serious diseases.
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
Epicrispr Biotechnologies62BiotechnologySouth San Francisco, United States$90.0MEpicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
- Website
Degron Therapeutics62BiotechnologySan Diego, USA$40.0MClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
- Website
Adcendo60BiotechnologyCopenhagen, Denmark$272.0MDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
- Website
Enterome60BiotechnologyParis, France$123.9MClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
Celerion59BiotechnologyLincoln, USA$45.0MA global leader in clinical pharmacology and bioanalytical sciences.
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website LŌLōkahi Therapeutics57BiotechnologyLa Jolla, USA$63.0M
A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.
- Website
Janux Therapeutics57BiotechnologySan Diego, USA$181.0MA clinical-stage biopharmaceutical company developing novel immunotherapies.
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- EAEarendil Labs56BiotechnologyBeijing, China$787.0M
Earendil Labs is an AI biotechnology company focused on leveraging artificial intelligence for drug discovery and development of next-generation biologics.
- Website
Anagram Therapeutics55BiotechnologyNatick, USA$285.0MClinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.
- Website
Cellares54BiotechnologySouth San Francisco, USA$327.0MThe first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.
- Website
Gossamer Bio54BiotechnologySan Diego, USA$150.0MA biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.
Showing the 20 closest matches. See the rest on the Viridian Therapeutics, Inc. profile.
Compare Viridian Therapeutics, Inc. head to head
Side by side on what each one does, what it costs, and what real users report.